SDH-Engine

Drug Repurposing Engine

DashboardDrug CandidatesAI HypothesesResearch FeedClinical TrialsAbout / Methods

Targeting SDH-deficient GIST, paraganglioma, pheochromocytoma, RCC

This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

3 candidates mapped to SDH-deficient disease pathways

All (65)established (7)clinical trial (13)preclinical (13)theoretical (32)
Telaglenastat

CB-839

clinical trial

Glutaminase inhibitor

Glutamine Dependency
All SDH tumors
Evidence Score
60
2 trials
Denifanstat

TVB-2640

preclinical

FASN inhibitor (fatty acid synthase inhibitor)

De Novo LipogenesisGlutamine Dependency
All SDH tumors
Evidence Score
35
2 trials
Bempedoic Acid

Nexletol, Nilemdo

theoretical

ACLY inhibitor (ATP-citrate lyase inhibitor, prodrug)

Reductive CarboxylationGlutamine Dependency
All SDH tumors
Evidence Score
23
FDA Approved